HematologyIn Clinical Trials

Hepcidin

Subcutaneous injection

Overview

Hepcidin is a 25-amino acid endogenous peptide hormone produced primarily by hepatocytes that serves as the master regulator of systemic iron homeostasis. It binds to ferroportin, the sole known cellular iron exporter, inducing its internalization and degradation, thereby blocking iron release from enterocytes, macrophages, and hepatocytes.

Mechanism of Action

Therapeutic hepcidin agonists and antagonists are being developed to treat iron overload disorders and anemia of chronic disease, respectively..

Research Summary & Key Findings

Hepcidin was first characterized in 2001 (Blood, JCI) as a key iron regulatory hormone. Multiple hepcidin mimetics and antagonists have entered Phase 1 and Phase 2 clinical trials for conditions including beta-thalassemia, polycythemia vera, and anemia of chronic kidney disease, though none have yet achieved regulatory approval.

Clinical Status

In Clinical Trials

Hepcidin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Hematology

Find a Provider

Find a verified provider who offers Hepcidin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Hepcidin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.